Small study aims to unlock secrets of rare lung disease
NCT ID NCT00098072
First seen Jun 25, 2026 · Last updated Aug 05, 2026 · Updated 8 times
Summary
This completed Phase 1 study looked at 27 people with and without pulmonary hypertension to learn more about how blood vessel problems contribute to the disease. Researchers used heart catheterization, imaging, and blood tests to find biomarkers and understand disease mechanisms. The goal was to improve detection and treatment, not to test a new drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could point toward better ways to detect and treat pulmonary hypertension, and possibly slow its progression.
- What could go wrong
- This is an early, small study focused on understanding the disease, not testing a new treatment. It may not lead directly to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLLAGEN VASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scoliosis's hidden toll: can we predict lung and heart risks?
- Can a new pill ease the strain of pulmonary arterial hypertension?
- Which breathing setting keeps Kids' lungs healthier during heart surgery?
- Could a simple sleep guide ease insomnia in lung disease?
- Can extra doses of an old drug reverse liver scarring?
- Can Co-Designed support help parents embrace sickle cell care?